LGND News and Press, Ligand Pharmaceuticals Incorporated From 03/21/19

ZULRESSO is the first and only treatment specifically indicated for postpartum depression Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of ...

It has only been a few months since my first Seelos article ( SEEL ), but the company has been negotiating two deals to expand its pipeline and areas of study. The first deal was made in February with Bioblast Pharma ( ORPN ) concerning their mutant protein stabilization solution called Treh...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Barclays Global Healthcare Conference in Miami. Presentation takes place on Wednesday, March 13, 2019 at 9:00 a.m. Eastern...

COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer Dr. David Portman will ...

Investors appear disappointed with Ligand Pharmaceuticals' ( LGND -11.6% ) agreement to sell its rights to  Promacta (eltrombopag) to Royalty Pharma for $827M in cash. The company plans to reinvest the proceeds to acquire assets with long-term revenue streams, fully funded "shots o...

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 66 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This i...

Updates 2019 full-year financial guidance Conference call with slides to be held today at 5:00 p.m. Eastern time Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta ® -related intellectual property rights lice...

COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a poster on the performance of its lead investig...

Ligand Pharmaceuticals (LGND) share price has fallen more than 50% since September, and on January 16, Citron Research published a report questioning the credibility of Ligand's pipeline data and optimism, which led to another sharp decline of the share price. However, the share price recove...

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 64 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...